Cepollaro C, Gonnelli S, Rottoli P, Montagnani A, Caffarelli C, Bruni D, Nikiforakis N, Fossi A, Rossi S, Nuti R
Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Siena, Italy.
Osteoporos Int. 2005 Jul;16(7):743-8. doi: 10.1007/s00198-004-1741-z. Epub 2004 Oct 1.
Osteoporosis is one of the major complications of glucocorticoid (GC) therapy. Few data are available on the usefulness of quantitative ultrasound (QUS), a technique that could also theoretically provide information on bone structure, in the management of glucocorticoid-induced osteoporosis (GIO). This study aimed (1) to evaluate the ability of QUS in detecting bone impairment and in being associated with the prevalence of fragility fracture in GC patients; and (2) to assess whether QUS parameters, and particularly the graphic trace analysis of QUS signal at phalanges, show any peculiar pattern of GIO. We studied 192 patients (136 women and 56 men, mean age 56.7 +/- 14.2 years) on treatment with GCs for at least 6 months, and 192 sex- and age-matched controls. In all subjects, we measured bone mineral density (BMD) at lumbar spine and at femur by DXA, and ultrasound parameters at calcaneus and phalanges. All DXA and QUS parameters were significantly lower in GC patients than in controls and in fracture than in nonfracture GC patients. BMD at lumbar spine showed the best ability in discriminating GC patients with or without fractures. Among QUS parameters, stiffness showed a discriminatory ability significantly better than AD-SoS. BMD at lumbar spine and total femur, stiffness, and AD-SoS are able to predict the odds of fragility fracture event. QUS parameters of the postmenopausal GC patients (n = 105) and of the postmenopausal healthy controls (n = 101) were also compared with those obtained in a separate sample of 90 postmenopausal osteoporotic women (PMO). All parameters were significantly lower in GC patients and in PMO than in controls, without any significant difference between GC and PMO. Our findings show that QUS can be useful in the assessment of glucocorticoid-induced bone impairment. In addition, in this study we found no alteration in QUS parameters or in the graphic trace analysis which could differentiate between GIO and PMO. Further longitudinal studies are needed to define the role of QUS in the prediction of fracture risk and in the clinical management of GIO.
骨质疏松症是糖皮质激素(GC)治疗的主要并发症之一。关于定量超声(QUS)在糖皮质激素性骨质疏松症(GIO)管理中的作用的数据很少,QUS这项技术理论上也可以提供有关骨结构的信息。本研究旨在:(1)评估QUS检测骨损伤以及与GC患者脆性骨折患病率相关性的能力;(2)评估QUS参数,特别是指骨QUS信号的图形轨迹分析,是否显示出GIO的任何特殊模式。我们研究了192例接受GC治疗至少6个月的患者(136名女性和56名男性,平均年龄56.7±14.2岁),以及192名性别和年龄匹配的对照者。在所有受试者中,我们通过双能X线吸收法(DXA)测量腰椎和股骨的骨密度(BMD),并测量跟骨和指骨的超声参数。所有DXA和QUS参数在GC患者中均显著低于对照组,在骨折患者中显著低于非骨折的GC患者。腰椎BMD在区分有或无骨折的GC患者方面表现出最佳能力。在QUS参数中,硬度的鉴别能力显著优于轴向声速(AD-SoS)。腰椎和全股骨的BMD、硬度和AD-SoS能够预测脆性骨折事件的几率。还比较了绝经后GC患者(n = 105)和绝经后健康对照者(n = 101)的QUS参数与从90名绝经后骨质疏松症女性(PMO)的单独样本中获得的参数。GC患者和PMO的所有参数均显著低于对照组,GC和PMO之间无任何显著差异。我们的研究结果表明,QUS可用于评估糖皮质激素引起的骨损伤。此外,在本研究中,我们未发现QUS参数或图形轨迹分析有任何改变可区分GIO和PMO。需要进一步的纵向研究来确定QUS在预测骨折风险和GIO临床管理中的作用。